What are the indications, dosing regimen, contraindications, and safety considerations for Xofluza (baloxavir marboxil) in patients aged 12 years or older?

Xofluza (Baloxavir Marboxil) for Influenza Treatment

Xofluza is FDA-approved for treating acute uncomplicated influenza in patients ≥5 years of age when initiated within 48 hours of symptom onset, administered as a single weight-based oral dose, and offers a compliance-friendly alternative to oseltamivir with comparable efficacy. 1, 2

Indications

Treatment

• Acute uncomplicated influenza in patients ≥5 years of age within 48 hours of symptom onset 1, 2
• Effective against both influenza A and B viruses 3
• Approved for both otherwise healthy patients and those at high risk for influenza complications 2

Post-Exposure Prophylaxis

• FDA-approved for patients ≥5 years of age within 48 hours of contact with an influenza-infected individual 3
• Consider when compliance is a concern or poor tolerance of multi-dose regimens 3

Dosing Regimen

Treatment Dosing (Single Oral Dose)

For patients ≥5 years:

• <20 kg: 2 mg/kg as single dose 1
• 20 kg to <80 kg: 40 mg as single dose 1
• ≥80 kg: 80 mg as single dose 1

Post-Exposure Prophylaxis Dosing

• Same weight-based dosing as treatment 1
• Must be initiated within 48 hours of exposure 1

Administration Considerations

• Administer orally or by feeding tube 1
• CRITICAL: Do NOT administer with:
  • Dairy products
  • Calcium-fortified beverages
  • Polyvalent cation-containing laxatives or antacids
  • Oral supplements containing calcium, iron, magnesium, selenium, or zinc 1

Contraindications and Precautions

Not Recommended For:

• Severely immunocompromised patients as monotherapy (due to risk of resistance emergence) 1
• Pregnant women 1
• Breastfeeding women 1

Important Safety Considerations

• Resistance emergence: Drug-resistant viruses developed in 5-7% of treated patients in clinical trials 3, 4
• Pediatric concerns: In children <6 years, symptom recurrence after day 4 occurred in 54.5% and fever recurrence in 50% in post-hoc analyses 3
• Oral suspension availability: The oral suspension formulation was not available in the US for the 2023-2024 season, limiting use in children <20 kg 3

Clinical Efficacy

Symptom Alleviation

Baloxavir demonstrates comparable efficacy to oseltamivir:

• In otherwise healthy adults: median time to symptom alleviation was 50-54 hours vs. 78-80 hours with placebo 2
• In high-risk patients: 73 hours vs. 102 hours with placebo 2, 4
• Superior efficacy against influenza B compared to oseltamivir in some trials 3

Viral Shedding

• Reduces viral shedding more rapidly than oseltamivir 3
• May reduce transmission to household contacts by 29% (adjusted relative risk reduction) 5

Adolescent Data (12-17 years)

• Median time to symptom alleviation: 54 hours vs. 93 hours with placebo 2
• Efficacy profile similar to adults 2

Adverse Events

Common adverse events (generally mild):

• Nausea 1, 2
• Vomiting 1, 2
• Diarrhea 1, 2
• Bronchitis 2
• Headache 1, 2

Safety profile comparable to placebo in clinical trials 4, 6

Clinical Positioning

When to Choose Xofluza Over Oseltamivir:

1. Compliance concerns - single dose vs. 5-day twice-daily regimen 3
2. Poor tolerance of multi-dose antiviral regimens 3
3. Influenza B infection - may have superior efficacy 3
4. Patient preference for single-dose therapy

When to Prefer Oseltamivir:

1. Severely immunocompromised patients (baloxavir not recommended as monotherapy) 1
2. Pregnant or breastfeeding women 1
3. Children <5 years (oseltamivir has broader age approval) 1
4. Concern about resistance emergence in high-risk settings

Key Clinical Pearls

• Timing is critical: Must initiate within 48 hours of symptom onset for both treatment and prophylaxis 1, 2
• Single-dose advantage: Eliminates adherence issues inherent with 5-day oseltamivir regimens 3
• Drug interactions: Avoid polyvalent cations which significantly reduce absorption 1
• Resistance monitoring: Clinicians should be aware of potential resistance emergence, particularly in immunocompromised patients 3, 4
• No renal dose adjustment needed for mild-to-moderate renal impairment 7